Loading clinical trials...

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01224015•Allergan

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Successfully completed Study 191622-099

Exclusion Criteria

•Known immunization or hypersensitivity to botulinum toxin of any serotype
•Anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment)
•Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
•Anticipated need for surgery or hospitalization during the study

Locations (4)

Newport Beach, California, United States

Vancouver, British Columbia, Canada

Antibes, France

Berlin, Germany

Key Dates

Start Date

May 1, 2011

Primary Completion Date

October 1, 2011

Completion Date

February 1, 2012

Last Updated

February 25, 2014

Enrollment

684

ACTUAL participants

Conditions

Facial RhytidesCrow's Feet LinesGlabellar Lines

Interventions

normal saline

DRUG

onabotulinumtoxinA 44 U

BIOLOGICAL

onabotulinumtoxinA 24 U

BIOLOGICAL

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement